149 related articles for article (PubMed ID: 27387240)
1. Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy.
Vera L; Gay S; Campomenosi C; Paolino S; Pera G; Monti E; Mortara L; Seriolo B; Giusti M
Endokrynol Pol; 2016; 67(4):350-8. PubMed ID: 27387240
[TBL] [Abstract][Full Text] [Related]
2. Assessment for bone health in patients with differentiated thyroid carcinoma after postoperative thyroid-stimulating hormone suppression therapy: a new fracture risk assessment algorithm.
Jia H; Qu W; Cai X; Li M; Qian Y; Jiang Z; Zhang Z
Front Endocrinol (Lausanne); 2023; 14():1286947. PubMed ID: 38075039
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
4. High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma.
Mazziotti G; Formenti AM; Frara S; Olivetti R; Banfi G; Memo M; Maroldi R; Giubbini R; Giustina A
J Clin Endocrinol Metab; 2018 Mar; 103(3):956-964. PubMed ID: 29121201
[TBL] [Abstract][Full Text] [Related]
5. Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study.
Wang S; Wang Y; Zhu L; He L; Lv M; Zhang H; Wang H; Zhang F; Lai Y; Li Y; Shan Z; Teng W
Endocrine; 2023 Jan; 79(1):113-124. PubMed ID: 36089636
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density in treated at a young age for differentiated thyroid cancer after Chernobyl female patients on TSH-suppressive therapy receiving or not Calcium-D3 supplementation.
Leonova TA; Drozd VM; Saenko VA; Mine M; Biko J; Rogounovitch TI; Takamura N; Reiners C; Yamashita S
Endocr J; 2015; 62(2):173-82. PubMed ID: 25374130
[TBL] [Abstract][Full Text] [Related]
7. Trabecular bone score in women with differentiated thyroid cancer on long-term TSH-suppressive therapy.
Sousa BÉCA; Silva BC; de Oliveira Guidotti T; Pires MC; Soares MMS; Kakehasi AM
J Endocrinol Invest; 2021 Oct; 44(10):2295-2305. PubMed ID: 33730348
[TBL] [Abstract][Full Text] [Related]
8. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
[TBL] [Abstract][Full Text] [Related]
9. Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments.
Grani G; Tumino D; Ramundo V; Ciotti L; Lomonaco C; Armillotta M; Falcone R; Lucia P; Maranghi M; Filetti S; Durante C
J Endocrinol Invest; 2019 Dec; 42(12):1485-1490. PubMed ID: 31203497
[TBL] [Abstract][Full Text] [Related]
10. Is there an interaction between socioeconomic status and FRAX 10-year fracture probability determined with and without bone density measures? Data from the Geelong Osteoporosis Study of female cohort.
Brennan SL; Quirk SE; Hosking SM; Kotowicz MA; Holloway KL; Moloney DJ; Dobbins AG; Pasco JA
Calcif Tissue Int; 2015 Feb; 96(2):138-44. PubMed ID: 25578145
[TBL] [Abstract][Full Text] [Related]
11. J-Shaped Association Between Postoperative Levothyroxine Dosage and Fracture Risk in Thyroid Cancer Patients: A Retrospective Cohort Study.
Shin DW; Suh B; Lim H; Yun JM; Song SO; Park Y
J Bone Miner Res; 2018 Jun; 33(6):1037-1043. PubMed ID: 29447437
[TBL] [Abstract][Full Text] [Related]
12. Spine bone texture assessed by trabecular bone score (TBS) predicts osteoporotic fractures in men: the Manitoba Bone Density Program.
Leslie WD; Aubry-Rozier B; Lix LM; Morin SN; Majumdar SR; Hans D
Bone; 2014 Oct; 67():10-4. PubMed ID: 24998455
[TBL] [Abstract][Full Text] [Related]
13. The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma.
Moon JH; Jung KY; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
Bone; 2016 Feb; 83():104-110. PubMed ID: 26518742
[TBL] [Abstract][Full Text] [Related]
14. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
[TBL] [Abstract][Full Text] [Related]
15. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
16. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
[TBL] [Abstract][Full Text] [Related]
17. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma.
Heijckmann AC; Huijberts MS; Geusens P; de Vries J; Menheere PP; Wolffenbuttel BH
Eur J Endocrinol; 2005 Jul; 153(1):23-9. PubMed ID: 15994742
[TBL] [Abstract][Full Text] [Related]
18. Body Composition, Resting Energy Expenditure, and Metabolic Changes in Women Diagnosed with Differentiated Thyroid Carcinoma.
Izkhakov E; Vaisman N; Barnes S; Barchana M; Stern N; Keinan-Boker L
Thyroid; 2019 Aug; 29(8):1044-1051. PubMed ID: 31088334
[No Abstract] [Full Text] [Related]
19. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
20. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma.
Kim MK; Yun KJ; Kim MH; Lim DJ; Kwon HS; Song KH; Kang MI; Baek KH
Bone; 2015 Feb; 71():101-5. PubMed ID: 25445448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]